SubHero Banner

Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) – Expanded indication and new contraindication

July 25, 2018 - The FDA approved Gilead’s Atripla (efavirenz/emtricitabine/ tenofovir disoproxil fumarate), as a complete regimen or in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg.

Download PDF